So Much to Lose: Changing landscape of obesity in America
Revisit our recorded webinar exploring obesity, weight loss, and the broader implications for sectors from healthcare to food and beverage.
Would you take a medication that would help you lose weight? That’s the question many Americans have been considering since a class of drugs known as GLP-1s (newer brands include Mounjaro, Ozempic, and Wegovy) became popularized by celebrities and influencers earlier this year.
According to the latest Ipsos Consumer Tracker, over half (54%) of Americans are interested in medication to help them lose weight. With two new GLP-1s now FDA approved for weight loss, there are broader implications for sectors from healthcare to food & beverage to airlines if America can find ways to treat its epidemics of obesity.
Listen in as our Ipsos experts deep dive into the implications of new obesity treatments, including:
- What Americans believe about obesity, and how that differs by demographics
- What Americans are discussing about obesity and obesity treatments
- Equity considerations regarding access to these treatments
- Implications for a broad set of industries
Speakers:
- Scott Morano, SVP, Ipsos Healthcare
- Chareen Lim, SVP Ipsos Healthcare
